0001209191-20-060721.txt : 20201130 0001209191-20-060721.hdr.sgml : 20201130 20201130160124 ACCESSION NUMBER: 0001209191-20-060721 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201125 FILED AS OF DATE: 20201130 DATE AS OF CHANGE: 20201130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cabell Christopher CENTRAL INDEX KEY: 0001814928 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 201358168 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-25 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001814928 Cabell Christopher C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 0 1 0 0 EVP, Head of R&D, and CMO Common Stock 2020-11-25 4 M 0 2500 0.00 A 2500 D Common Stock 2020-11-25 4 F 0 1099 65.50 D 1401 D Performance Restricted Stock Unit 2020-11-25 4 M 0 2500 0.00 D 2022-01-03 Common Stock 2500 5000 D On January 4, 2019, the Reporting Person was granted 5,000 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 2,500 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 2,500 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 5,000 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement. Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs. The amount reported in Column 7 of Table II represents the common shares that vested on November 25, 2020. The PRSUs' final Closing Price target has been met and the Reporting Person has a contingent right to receive 5,000 additional common shares if the subsequent continuing service requirement is met. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2020-11-30